Mifepristone Powder CAS 84371-65-3 Powder Raw Material

Related Attributes

Product details

Mifepristone Powder Usage and Synthesis:

Mifepristone CAS 84371-65-3, molecular formula: C29H35NO2, Mifepristone Powder Raw Material is Yellow solid. Mifepristone Powder has strong anti-progesterone activity, Mifepristone is a novel antiprogestin with antiglucocorticoid activity. Clinically, it can be used for anti-early pregnancy, inducing menstruation, and contraception afterward. Mifepristone, also known as antiprogesterone, Sibex, Siyin, containing chloridin, Simian, Minasterone, belongs to antiprogesterone drugs, is a new type of anti-fertility drugs acting on the level of receptors, without progesterone, androgen, estrogen activity. It mainly acts on the endometrioprogesterone receptor, which can bind to the progesterone receptor and glucocorticoid receptor, and has a high affinity. Its affinity for the endometrioprogesterone receptor is 5 times stronger than that of progesterone. At the effective dose, it has no significant effect on the cortisol level, and can produce strong anti-progesterone effect, resulting in degeneration of the deciduae and the vili tissues of pregnancy, and the release of endogenous prostaglandin. Lead to uterine contraction, at the same time can reduce the production of human chorionic gonadotropin, luteolysis, so that the embryo abortion.

Mifepristone Powder

Because the drug cannot cause enough uterine activity, the rate of incomplete abortion is high when it is used only for anti-early pregnancy, but it can increase the sensitivity of the uterus to prostaglandin. Therefore, adding a small dose of prostaglandin can not only reduce the adverse reaction of prostaglandin, but also significantly increase the rate of complete abortion. In addition, mifepristone also has the effect of softening and dilating the cervix. Clinical can be used for anti-early pregnancy, induce menstruation, after contraception, stillbirth induction and promote cervical maturity, can also be used for gynecological operations, such as the placement and removal of intrauterine device, endometrial specimen, cervical tube development abnormalities laser separation and cervical dilation and curettage.

Pharmacokinetics of Mifepristone Powder:

Mifepristone is a new type of anti-progesterone, and has the activity of anti-glucocorticoid, can be used for anti-early pregnancy, promote menstration and stop pregnancy, fetal death intrauterine induction of labor, and can also be used for gynecological surgery operations, such as the removal and placement of intrauterine device, removal of endometrial specimen, laser separation of cervical duct development abnormalities and cervical dilation and curettage.Pharmaceutical Raw Material Mifepristone can prevent implantation of fertilized eggs, induce menstruation, and promote cervical maturation. After clinical use, dizziness, nausea, vomiting, abdominal pain and other symptoms are easy to appear. The novel antiprogesterone has antiglucocorticoid activity, but no progesterone, estrogen, androgen and antiestrogen activity. And progesterone receptor affinity is 5 times stronger than progesterone. Used for anti-early pregnancy, menstruation stop pregnancy, fetal death official induction of labor, etc.

Mifepristone CAS 84371-65-3

Clinical Application of Mifepristone Powder:

Mifepristone can terminate pregnancy, prevent implantation, induce menstruation, and promote cervical maturation.

Mifepristone can also enhance the sensitivity of pregnant uterus to prostaglandin, can use small doses of mifepristone and prostaglandin drug sequential use, can achieve the effect of termination of early pregnancy.

Mifepristone can also be used for emergency contraception, such as during unprotected sex or within 72 hours of contraceptive failure, and for the preoperative treatment of uterine fibroids with severe symptoms in women of childbearing age.

Mifepristone is a receptor level antiprogesterone, which has the functions of terminating early pregnancy, anti-implantation, inducing menstruation and promoting cervical maturation. It competes with progesterone for receptor and achieves antagonistic effect of progesterone, and has certain binding force with glucocorticoid receptor. Mifepristone can significantly increase the sensitivity of pregnancy uterus to prostaglandin, low dose of mifepristone sequentially combined with prostaglandin drugs, can obtain satisfactory termination of early pregnancy effect.

Mifepristone CAS 84371-65-3